Latest News for: intravenous
Edit
First child death reported from flu this season in Virginia
Wtop 15 Jan 2026
Flu season has taken a grim turn in Virginia, as the state’s health department has reported the first death of a child caused by complications associated with influenza ... “Typically, activity starts in about October, maybe November ... Source .
Edit
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (ONO Pharmaceutical Co Ltd)
Public Technologies 14 Jan 2026
nivolumab) Intravenous Infusion ("Opdivo"), an anti-PD-1 antibody, on January 14 from the Taiwan Food and Drug Administration (TFDA) in Taiwan, in combination with ipilimumab, for the ...
Edit
Intravenous (IV) Solutions Market Size to Reach USD 25.10 Billion by 2033, Growing at a ...
Nasdaq Globe Newswire 09 Jan 2026
Global Intravenous (IV) Solutions Market growth is driven by rising hospitalization rates, ...
Edit
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) (Form 8-K) (Ovid Therapeutics Inc)
Public Technologies 18 Dec 2025
Edit
Intravenous Immunoglobulin Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | ...
GetNews 17 Dec 2025
The Key Intravenous Immunoglobulin Companies in the market include - Takeda, Mitsubishi Tanabe Pharma, AbbVie, Prothya Biosolutions, and others ... Some of the key facts of the Intravenous Immunoglobulin Market Report..
Edit
JFDA Bans Entry of Intravenous (+NAD) Products for Personal Use
Petra 10 Dec 2025
10 (Petra) The Jordan Food and Drug Administration (JFDA) said it has issued a circular prohibiting the entry of intravenous (+NAD) products for personal use, under legal liability, due to the absence ...
Edit
ER doctor: ‘No robust clinical evidence’ that IV hydration spa trend provides a safe pick-me-up
Wtop 04 Nov 2025
Edit
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
PR Newswire 28 Oct 2025
28, 2025 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.
Edit
ITC Syringe with Enlarged Inner Cone (EIC): Enhancing Compatibility for Intravenous (IV) Drug Delivery (Stevanato Group SpA)
Public Technologies 24 Oct 2025
Additional formats, including 1mL, 1.5mL, 3mL, and potentially 5mL, can be developed upon request ... [...]. This is an abstract of the document ... Attachments Original document Permalink. Disclaimer.
- 1